A phase I study of EP-100, a luteinizing hormone releasing hormone (LHRH) ligand conjugated to a synthetic cytolytic peptide in patients with advanced refractory LHRH- receptor (R)-expressing tumors.
Ramesh K. Ramanathan
Research Funding - Esperance Pharmaceuticals
Manpreet Chadha
No relevant relationships to disclose
John Sarantopoulos
Research Funding - Esserance Pharmaceuticals
Donald W. Northfelt
No relevant relationships to disclose
Glen J. Weiss
No relevant relationships to disclose
Monica M. Mita
Research Funding - Esperance Pharmaceuticals
Kerry M. Barnhart
Consultant or Advisory Role - Esperance Pharmaceuticals
John Whisnant
Employment or Leadership Position - Esperance Pharmaceuticals
Consultant or Advisory Role - Esperance Pharmaceuticals
Carola Leuschner
Employment or Leadership Position - Esperance Pharmaceuticals
Stock Ownership - Esperance Pharmaceuticals
Hector Alila
Employment or Leadership Position - Esperance Pharmaceuticals
Stock Ownership - Esperance Pharmaceuticals
Kelly Kevelin Curtis
Research Funding - Esperance Pharmaceuticals